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790Background: Low cardiac output syndrome is defined as the need for a postoperative intra-aortic balloon pump
or inotropic support for longer than 30 minutes in the intensive care unit. Mitral valve surgery is increasingly
being performed in high-risk patients who might require mechanical circulatory support for low cardiac output
syndrome. Therefore the aim of this study was to identify the preoperative predictors of low cardiac output
syndrome after mitral valve surgery.
Methods: We conducted a retrospective review of data prospectively entered into an institutional database.
Between 1990 and February 2008, 3039 patients underwent isolated mitral valve surgery with or without coro-
nary bypass surgery. The independent predictors of low cardiac output syndrome and operative mortality were
determined by means of stepwise logistic regression analysis.
Results: The overall prevalence of low cardiac output syndrome was 7%. The independent predictors of low
cardiac output syndrome were urgency of the operation (odds ratio, 2.9), earlier year of operation (odds ratio,
2.4), left ventricular ejection fraction of less than 40% (odds ratio, 2.1), New York Heart Association class IV
(odds ratio, 2), body surface area of 1.7 m2 or less (odds ratio, 1.6), ischemic mitral valve pathology (odds ratio,
1.6), and cardiopulmonary bypass time (odds ratio, 1.02). The operative mortality was higher in patients with low
cardiac output syndrome (30% vs 1.3%, P< .001). Overall operative mortality was 3.4%. The independent
predictors of mortality were urgency of the operation (odds ratio, 7.1), renal failure (odds ratio, 4.3), nonuse
of polytetrafluoroethylene sutures (Gore-Tex; W. L. Gore & Associates, Inc, Austin, Tex; odds ratio, 2.1), any
reoperative surgical intervention (odds ratio, 1.8), increasing age (odds ratio, 1.03), and cardiopulmonary bypass
time (odds ratio, 1.02).
Conclusions: Low cardiac output syndrome is associated with significantly increased morbidity and mortality.
Novel strategies to preserve renal function, optimization of pre-existing heart failure symptoms, and use of
artificial polytetrafluoroethylene sutures might reduce the incidence of low cardiac output syndrome and lead
to improved results after mitral valve surgery. (J Thorac Cardiovasc Surg 2010;140:790-6)Earn CME credits at
http://cme.ctsnetjournals.org
Low cardiac output syndrome (LCOS) has been previously
characterized by our group in patients undergoing isolated
coronary bypass surgery and aortic valve surgery.1,2 As
the proportion of patients undergoing mitral valve surgery
with poor preoperative left ventricular (LV) function con-
tinues to increase,3 we wished to identify the predictors of
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The Journal of Thoracic and Cardiovascular Surgnificant proportion of patients undergoing high-risk mitral
valve surgery might be candidates for more advanced surgi-
cal therapies for heart failure, including mechanical circula-
tory support and transplantation. Preoperative prediction of
the need for advanced support might allow for a discussion
regarding ultimate treatment options. Patients who are
screened and found not to be suitable transplant candidates
can then be offered short-term temporary support in the
hopes of myocardial recovery or long-term implantable
devices as destination therapy. Lastly, identification of
a high-risk subset might dictate preoperative optimization
by the use of diuretic therapy, afterload reduction, and/or in-
tra-aortic balloon pump (IABP) support.MATERIALS AND METHODS
Data Source
Approval was obtained from our institutional research ethics board to
perform a retrospective, clinical chart review. Clinical, operative, and out-
come data were collected prospectively in a computerized institutional da-
tabase on all patients undergoing cardiac surgery. We conducted
a retrospective review of our institutional database to identify patients
who underwent mitral valve surgery. Between 1990 and February 2008,ery c October 2010
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FIGURE 1. Prevalence of low cardiac output syndrome (LCOS).
Abbreviations and Acronyms
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
CBP ¼ cardiopulmonary bypass
IABP ¼ intra-aortic balloon pump
LCOS ¼ low cardiac output syndrome
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
MI ¼ myocardial infarction
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
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without coronary bypass surgery.
Explanatory Variables
Core baseline explanatory variables collected since 1990 included the
following: age; sex; LV grade (based on left ventricular ejection fraction
[LVEF]: grade 1, LVEF>60%; grade 2, LVEF 40% to 59%; grade 3,
LVEF 20% to 39%; grade 4, LVEF<20%); urgency of the operation (elec-
tive; semiurgent, indicating an operation during the same admission as a car-
diac catheterization or a cardiac event; urgent, indicating an operation
within 72 hours of an event; or emergency, indicating an operation within
12 hours of an event); New York Heart Association (NYHA) class; mitral
valve lesion (stenotic, regurgitant, or mixed, as determined by means of
echocardiographic analysis); and infective endocarditis (active endocarditis,
active endocarditis with abscess formation, remote endocarditis, or none).
LVEF was measured by using ventriculographic or echocardiographic anal-
ysis, and the most recent preoperative value was recorded. Other explana-
tory variables collected to more fully characterize these patients included
recent myocardial infarction (MI), diabetes, dyslipidemia, peripheral vascu-
lar disease, history of hypertension, preoperative stroke, or transient ische-
mic attack. Details of this database have been published previously.1-3
Study Outcomes
Our primary outcomes in this study were LCOS and operative mortality.
Operative mortality was defined as any postoperative death occurringwithin
30 days or during the same hospital admission. LCOS was diagnosed if the
patient required an IABP to be weaned from cardiopulmonary bypass (CPB)
or in the intensive care unit because of hemodynamic compromise. LCOS
was also diagnosed if the patient required inotropic medication (either dopa-
mine, dobutamine, milrinone, or epinephrine) to maintain systolic blood
pressure at greater than 90 mm Hg and cardiac output at greater than
2.2 L $ min1 $ m2 for at least 30 minutes in the intensive care unit after
correction of all electrolyte and blood gas abnormalities and after adjusting
the preload to its optimal value.4 Afterload reduction was also attempted
when possible. Patients who received less than 4 mg/kg dopamine to
increase renal perfusion were not considered to have LCOS. Patients who
received vasoconstricting medications because of a high cardiac output
(2.5 L $ min1 $ m2) and low peripheral resistance were also not consid-
ered to have LCOS. In patients who received an IABP before surgical inter-
vention, LCOS was determined if they required significant postoperative
inotropic support, as described above, in addition to IABP support.
Statistical Analysis
Statistical analysis was done with SAS 9.2 software (SAS Institute, Inc,
Cary, NC). c2 Tests were used to evaluate categoric data univariately when
the minimum number of observations in a category was greater than 5;The Journal of Thoracic and Caotherwise, the Fisher’s exact test was used. Categoric variables were
expressed as percentages. Student’s t test was used to analyze continuous
variables that had normal distribution, and the Wilcoxon rank test was
used for variables that had nonparametric distribution. Continuous variables
were expressed as means standard deviations. Variables that had a univar-
iate P value of less than .25 or those judged to be clinically important were
selected for inclusion in a logistic regression model by means of stepwise
selection. Multivariable logistic regression methods were used to calculate
factor-adjusted odds ratios and to determine the independent predictors of
LCOS and operative mortality. Model discrimination was evaluated by
the area under the receiver operating characteristic curve, and calibration
was assessed with the Hosmer–Lemeshow goodness-of-fit statistic.
RESULTS
Demographics
The study population (n ¼ 3039) was divided into 3 eras
based on the year of the operation (1990–1995, n ¼ 839;
1996–2001, n ¼ 1103; and 2002–February 2008, n ¼ 1097)
to account for a changing pattern of outcomes over time.
LCOS developed in 7% (n ¼ 213) of all patients. There
were 87 patients who received an IABP preoperatively, of
whom43were deemed to have hadLCOSbecause of the post-
operative need for inotropic support. The prevalence of LCOS
has decreased over time (Figure 1). The preoperative charac-
teristics of the patients who did and did not have LCOS are
provided inTable 1. The results of univariate analysis revealed
that LCOS was significantly associated with year of the oper-
ation, increasing age, urgency of the operation, NYHA class,
diabetesmellitus, hypertension, cardiogenic shock, congestive
heart failure, syncope, poor LVEF, MI, stroke, renal failure,
angina, chronic obstructive pulmonary disease, peripheral
vascular disease, reoperative surgery, concomitant coronary
artery bypass grafting (CABG), left main disease, and ische-
mic mitral valve pathology. Patients who had mitral valve
replacement had a higher incidence of LCOS compared with
patientswhohadmitral valve repair.No significant differences
wereobservedamong the types ofmitral valve lesion: stenosis,
regurgitation, or mixed. Only a small proportion of patientsrdiovascular Surgery c Volume 140, Number 4 791
TABLE 1. Distribution of preoperative variables
Variable No LCOS (%) LCOS (%) P value
No. of patients 2820 213
Year of operation
1990–1995 26.4 47.4 <.001
1996–2001 37.1 31.8
2002–February 2008 36.5 20.8
Age (y) 59  14 64  12 <.001
Sex
Male 54.4 49.8 .2
Female 45.6 50.2
Body surface area
1.7 m2 28.1 37.3 .009
>1.7 m2 71.3 62.7
NYHA class
I 10.3 1.9 <.001
II 26.4 9.9
III 42.4 26.7
IV 20.9 61.5
Diabetes mellitus 9.8 18.3 <.001
Hypertension 32.3 39.3 .03
Dyslipidemia 28.8 31.4 .4
Cardiogenic shock 1.9 17.5 <.001
Congestive heart failure 54.9 77.8 <.001
Syncope 2.2 9.4 <.001
LVEF <.001
>60% 55.6 24.1
40% to 60% 31.9 38.6
<40% 12.5 37.3
Myocardial infarction 3.1 22.2 <.001
Stroke 10.4 15.6 .02
Renal failure 1.4 7 <.001
Angina 19.2 48.8 <.001
Chronic obstructive
pulmonary disease
5.1 11.3 .0002
Peripheral vascular disease 4.9 18.8 <.001
Reoperative surgical
intervention
16.2 28.2 <.001
Concomitant CABG 26.9 57.3 <.001
Left main disease 2.9 10.8 <.001
Urgency of operation
Elective 77.7 38.5 <.001
Same hospital 16.1 27.7
Urgent/emergency 6.2 33.8
Mitral valve surgery
Repair 52.3 22 <.001
Replacement 47.7 78
Mitral valve/prosthesis lesion (%)
Stenosis 10.8 10.5 .7
Regurgitation 77.1 78.6
Mixed 11.2 9.5
Ischemic mitral
valve pathology
10.8 36.9 <.001
Infective endocarditis (%)
Active or active, abscess 3 4.2 .3
LCOS, Low cardiac output syndrome; NYHA, New York Heart Association; LVEF,
left ventricular ejection fraction; CABG, coronary artery bypass grafting.
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and the proportion was similar between the groups.
Intraoperative Data
Details of operative procedures are listed in Table 2.
Patients with LCOS had smaller body surface areas and
received a higher proportion of valve replacements. Mitral
valve annular reconstruction and chordal preservation
were higher in patients who had LCOS. However, the use
of polytetrafluoroethylene (Gore-Tex; W. L. Gore &Associ-
ates, Inc, Austin, Tex) sutures was higher in patients without
LCOS. Durations of CPB and crossclamp time were longer
in patients with LCOS.
Postoperative Outcomes
The overall mortality rate was 3.4% (n ¼ 102). Among
the 102 deaths, 82 patients died of cardiac reasons, and 20
patients died of noncardiac causes. In the LCOS group
83% (53/64) of patients experienced cardiac deaths, whereas
in the non-LCOS group 76% (29/38) had cardiac deaths.
Operative mortality was higher in patients with LCOS
(30%) than in patients without LCOS (1.3%, P< .001).
Postoperative length of stay and hospital outcomes are
summarized in Figures 2 and 3. The LCOS group required
longer ventilatory support and longer postoperative intensive
care unit and hospital stay compared with the non-LCOS
group (Figure 2). The incidence of postoperative complica-
tions, such as stroke, MI, reoperation for bleeding, and renal
failure, was higher in patients with LCOS than in patients
without LCOS (Figure 3). Patients with LCOS also had a sig-
nificantly higher rate of pulmonary complications (35% vs
10%, P< .001) and sepsis (11% vs 0.9%, P< .001).
Predictors of LCOS
Multivariable logistic regression analysis identified 7
independent predictors of LCOS: small body surface area,TABLE 2. Distribution of intraoperative variables
Variable No LCOS (%) LCOS (%) P value
No. of patients
Valve type
Mechanical 30.2 41.3 <.001
Bioprostheses 17.5 36.6
Valve repairs 52.3 22.1
Body surface area (m2) 1.83  0.24 1.78  0.23 .006
Mitral valve
annular reconstruction
3.8 8.9 <.001
Chordal preservation (%)
Posterior only 16.2 25 <.001
Anterior and posterior 11.5 22.5
Use of PTFE sutures 44.5 22.2 <.001
Duration of CPB (min) 95  36.5 141  54.2 <.001
Duration of XCL (min) 73  30.3 98  39.5 <.001
LCOS, Low cardiac output syndrome; PTFE, polytetrafluoroethylene; CPB,
cardiopulmonary bypass; XCL, aortic crossclamp.
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FIGURE 2. Mean length of stay. LCOS, Low cardiac output syndrome.
TABLE 3. Multivariable predictors of low cardiac output syndrome
Variable Odds ratio 95% CI P value
Urgent/emergency vs elective
operation
2.9 1.6–5 .0002
Earlier year
of operation, 1990–1995 vs
2002–2007
2.4 1.5–3.7 <.001
Left ventricular
ejection fraction<40%
2.1 1.3–3.3 .004
NYHA class IV 2 1.2–3.2 .005
BSA 1.7 vs>1.7 m2 1.6 1.2–2.3 .005
Ischemic mitral
valve pathology
1.6 1.1–2.4 .02
Duration of CPB 1.02 1.01–1.02 <.001
CI, Confidence interval; NYHA, New York Heart Association; BSA, body surface area;
CPB, cardiopulmonary bypass.
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earlier year of operation, NYHA class IV, ischemic mitral
valve pathology, and duration of CPB. Table 3 presents
the odds ratios, 95% confidence intervals, and P values
associated with the above-mentioned variables. The step-
wise logistic model was robust, with an area under the
receiver operating characteristic of 0.84 and a Hosmer–
Lemeshow goodness-of-fit P value of .42, indicating good
model discrimination and calibration.Operative Mortality
The results of univariate analysis showed that operative
mortality was significantly higher in diabetic patients (6.6%
vs 2.9%, P< .001), patients with hypertension (4.7% vsFIGURE 3. Hospital outcomes. LCOS, Low cardiac output syndrome.
The Journal of Thoracic and Ca2.6%, P ¼ .002), patients undergoing emergency or urgent
operations (17.5% vs 1.3%, P< .001), patients with an
LVEF of less than 40% (9.7% vs 1.4%, P< .001), patients
with NYHA class IV symptoms (9.5% vs 1.4%, P< .001),
patients who had a preoperative stroke or transient ischemic
attack (5.8% vs 3.1%, P ¼ .009), patients with peripheral
vascular disease (14% vs 2.7%, P<.001), patients with con-
gestive heart failure (4.8% vs 1.4%, P< .001), patients
with chronic obstructive pulmonary disease (8.8% vs 3%,
P< .001), patients who had preoperative shock (29.4% vs
2.6%, P< .001), patients who had preoperative MI (18.5%
vs 2.6%, P< .001), patients with preoperative renal failure
(30.4% vs 2.9%, P< .001), patients undergoing a repeat
operation (6.6% vs 2.7%, P < .001), patients with left
main disease (10.6% vs 3.1%, P<.001), patients with infec-
tive endocarditis (9.6% in patients with active endocarditis or
active abscess vs 3.2% in patients with remote or no endocar-
ditis, P< .001), patients undergoing concomitant CABG
(6.8% vs 2%, P< .001), patients with ischemic mitral valve
pathology (9.8% vs 2.4%, P<.001), patients who had mitral
valve replacement compared with mitral valve repair (5.7%
vs 0.99%, P< .001), and patients in whom no polytetra-
fluoroethylene sutures were used (5% vs 0.93%, P< .001).
Operativemortality in patients who had postoperative compli-
cations are summarized in Table 4.
Patients who died postoperatively were older (66  14 vs
59  14 years, P< .001), had smaller body surface areas
(1.78  0.26 vs 1.83  0.24 m2, P ¼ .03), required longer
CPB times (155  58 vs 96  38 minutes, P< .001), had
a longer postoperative intensive care unit stay (230  302
vs 58  90 hours, P< .001), required more hours of venti-
lator support (185  266 vs 23  116 hours, P< .001), and
stayed longer in the hospital postoperatively (12.8  15 vs
10.3  7.7 days, P ¼ .03).
Predictors of Operative Mortality
Stepwise logistic regression analysis identified timing of
the operation, small body surface area, nonuse ofrdiovascular Surgery c Volume 140, Number 4 793
TABLE 4. Postoperative complications
Postoperative
complication No. of patients
Associated operative
mortality (%) P value
Myocardial infarction 40 27.5 <.001
Stroke 55 23.6 <.001
Re-exploration <.001
Bleeding 125 7.2
Tamponade 31 19.3
Redo operation 14 0
Shock/arrest 10 70
Infection 8 12.5
Dehiscence 4 26.7
Other 15 0
Sepsis 48 37.5 <.001
Pulmonary complications 359 11.4 <.001
Renal failure 52 69.2 <.001
TABLE 5. Multivariable predictors of operative mortality
Variable Odds ratio 95% CI P value
Urgent/emergency vs elective
operation
7.1 3.9–12.7 <.001
Same-day hospitalization
vs elective operation
2 1.1–3.6 .02
Renal failure 4.3 2–9.4 <.001
Nonuse of PTFE sutures 2.1 1.1–3.9 .03
Any reoperative
surgical intervention
1.8 2–9.4 <.001
Duration of CPB 1.02 1.016–1.024 <.001
Increasing age 1.03 1.01–1.05 .007
CI, Confidence interval; PTFE, polytetrafluoroethylene; CPB, cardiopulmonary
bypass.
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creasing age as 6 independent predictors of operative mortal-
ity. Odds ratios associated with these variables, along with
95% confidence intervals and P values, are provided in
Table 5. The logistic regression model for operative mortal-
ity had good model discrimination, with an area under the
curve of 0.89, and good model calibration, with a Hosmer-
Lemeshow goodness-of-fit P value of .35.DISCUSSION
The present study examined the clinical outcomes of
a large consecutive series of patients undergoing mitral
valve replacement or repair over an 18-year period. We
have not found any other articles in the literature identifying
the predictors of LCOS in patients undergoing mitral valve
surgery. The prevalence of LCOS decreased over time, as re-
ported previously in our published article on examining the
predictors of LCOS in aortic valve operations.1 However,
the postoperative morbidity and mortality associated with
LCOS continues to be significant, as shown in Figure 3.
Also, the mortality associated with the development of
LCOS is on the increase, from 23% (23/100) in the earliest
era to 35% (16/46) in the most recent era.
The effect of LCOS in a valvular population is more dra-
matic than that reported in patients undergoing isolated
CABG.2 Compared with a 17-fold increase in patients
undergoing CABG, LCOS portended a 38-fold increase in
mortality after aortic valve surgery and a 30-fold increase
in this study.1 Although the development of LCOS was as-
sociated with a significant increase in operative mortality,
from 1.3% to 30%, the independent predictors of LCOS
and mortality were not alike. In comparison with similar
studies performed by our group in patients undergoing aortic
valve surgery or isolated CABG, the predictors of LCOS
after mitral valve surgery are significantly different.
In this patient population the most significant predictor
of LCOS and operative mortality was the timing of the794 The Journal of Thoracic and Cardiovascular Surgoperation. Patients undergoing operations on an urgent or
emergency basis had significantly higher rates of LCOS
and operative mortality. These patients are likely to have
several other comorbidities, which might lead to a higher in-
cidence of LCOS and operative mortality. Our results are in
agreement with published reports by Nowicki and col-
leagues,5 who reported an urgent and emergency presenta-
tion as one of the most important risk factors for death
after mitral valve surgery. Similarly, Jamieson and associ-
ates,6 who developed risk strata for postoperative mortality
after cardiac valve replacement, also identified emergency
status as one of the most important predictors.
Earlier year of operation emerged as one of the significant
predictors of LCOS, which is consistent with our previously
documented improvements in cardiac surgical outcomes
over time.1,7 Decreased LVEF came out as one of the signif-
icant predictors of LCOS, but the influence of LVEF is less
significant in patients undergoing mitral valve surgery
(odds ratio, 2.1) compared with the CABG (odds ratio,
5.7) or aortic valve (odds ratio, 3.6) groups, as published
in our previous reports.3,4 In our study poor preoperative
LVEF is associated with a higher incidence of LCOS in pa-
tients with mitral insufficiency than in patients with mitral
stenosis (21% vs 10.3%, respectively). In a recent study
published by Mirabel and coworkers,8 impaired LVEF is re-
ported as one of the factors to deny surgical intervention in
patients with severe symptomatic mitral regurgitation (MR).
However, the authors do not justify the decision according to
current knowledge based on American College of Cardiol-
ogy/American Heart Association guidelines. Furthermore,
low LVEF is found to be a predictive variable of sudden
mortality9-11 and late perioperative mortality12 in patients
with MR. Unfortunately, MR can mask underlying LV dys-
function. Although noninvasive assessments of LV function
might appear to be normal, often, LV function is impaired,
which manifests itself after mitral competence is restored.
NYHA class IV emerged as one of the predictors of LCOS
but not operative mortality. In fact, of the many studies that
reported risk factors for operative mortality after mitral valveery c October 2010
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major risk factors. These results confirm the previous obser-
vations that perioperative outcomes are usually worse in
patients with severe symptomatic conditions.13–16 Smaller
body surface area was also attributed to a higher incidence
of LCOS. Previous studies in patients undergoing CABG
have hypothesized an increased risk in female patients
because of their smaller body size and correspondingly small
coronary anatomy.17,18 The relationship between body
surface area and LCOS in a valvular population is unclear.
Kenchaiah and colleagues19 reported that patients with
a body mass index (BMI) of less than 23 enrolled in the
Candesartan in Heart Failure: Assessment of Reduction in
Mortality in Morbidity study had a significantly poorer sur-
vival. Accurate BMI data were available for 2601 (86%)
members of this population, and of these, 698 (27%) had
a BMI of less than 23. These data suggest that a significant
proportion of our patients might have had cardiac cachexia
reflecting the end stage of their valvular disease.
Ischemic mitral valve pathology also emerged as a signifi-
cant risk factor for LCOS. It has been well documented that
patients with ischemicMRhave aworse survival than patients
without ischemic MR.20-22 Importantly, postoperative sur-
vival is inversely correlated to the degree of ischemic MR.20
Duration ofCPB also emerged as an independent risk factor
for postoperative LCOS and mortality. Longer CPB times
likely act as a surrogate for technical difficulties during surgi-
cal intervention or poor myocardial function requiring longer
reperfusion times. The fact that aortic crossclamp time did not
emerge as a predictor likely supports the latter hypothesis.
Apart from duration of CPB time and the urgency of the
operation, which are mentioned above, renal failure, nonuse
of polytetrafluoroethylene sutures, previous cardiac surgery,
and increasing age significantly predicted operative mortal-
ity in the present patient population.
Renal failure and previous surgical intervention are
widely reported as major risk factors of operative mortality
in cardiac valve operations. Jamieson and assocoiates6 pub-
lished independent predictors of operative mortality in
86,580 patients undergoing valve replacements using the
Society of Thoracic Surgeons database. Their study identi-
fied renal failure and reoperations as high-level risk factors.
Similarly, Herzog and cowrkers23 identified more than 5000
dialysis patients undergoing aortic valve surgery, mitral
valve surgery, or both through the US Renal Data System
over a 20-year period. The perioperative mortality was
greater than 20%, and the 2-year survival rate was only
40%, irrespective of whether a mechanical or tissue valve
was implanted. Several studies have examined various renal
protective strategies in an isolated CABG population; how-
ever, no single strategy has emerged as clearly beneficial.24
It is unclear whether perioperative dopamine, vasopressin,
or N-acetylcysteine would prove to be more beneficial in
patients undergoing mitral valve surgery.The Journal of Thoracic and CaSimilar to renal failure and reoperations, advanced age is
also reported as one of the most important predictors of op-
erative mortality in patients undergoing mitral valve opera-
tions.25-28 These reports emphasize the significance of age
as one of the important factors in clinical decision making.
Indeed, Mirabel and coworkers8 reported advance age as
one of the factors to deny surgical intervention in patients
with severe MR in the Euro heart survey on valvular disease.
Interestingly, the use of polytetrafluoroethylene artificial
chordae was found to protect against the development of
both postoperative low output syndrome and operative mor-
tality. When stratified by repair or replacement, polytetra-
fluoroethylene chordae were found to be beneficial in both
groups. We have previously reported that the preservation
of chordae tendinae leads to improved early and late out-
comes after mitral valve replacement, presumably because
of improved papillary muscle–annular interactions.29,30
However, the mechanism by which artificial chordae im-
proves LV function and reduces operative mortality in pa-
tients undergoing mitral valve repair is unclear and
deserves further investigation. Although the use of polytetra-
fluoroethylene sutures was practiced throughout the duration
of the study, use did increase (1990–1995, 37%; 1996–
2001, 43%; and 2002–2007, 48%; P< .001).
In summary, this study is the first to distinguish the
preoperative predictors of postoperative LCOS from those
of operative mortality in a population of patients undergoing
mitral valve surgery. In agreement with our previous study
examining aortic valve surgery, the development of postop-
erative LCOS is associated with significant morbidity and
mortality.
The clinical implications of this study are multifaceted.
Preoperative risk profiling and patient selection will always
benefit from repeated analyses of institutional results. How-
ever, an additional objective of this study was to predict
those patients who might require mechanical circulatory
support in the early postoperative period. During the time
period of this study, we did not offer mechanical circulatory
support to those patients with postcardiotomy shock unless
the patient was prescreened before intervention and found
to be a suitable transplant candidate. No patient who under-
went mitral valve surgery with ‘‘left ventricular assist device
backup’’ required temporary mechanical support other than
an IABP.
Despite the prospective nature of the data collection, this
study remains a retrospective review of a single center’s ex-
perience and suffers from all of the caveats of such a study.
We did not examine the effect of altered surgical decision
making because of perceived risk (eg, repair vs replace or
mechanical vs tissue valve). Furthermore, although we re-
stricted our analysis to isolated mitral valve surgery, there
are several diverse patient populations within our cohort,
each with a varied level of operative risk (eg, myxomatous
vs ischemic).rdiovascular Surgery c Volume 140, Number 4 795
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NYHA functional class, poor preoperative LVEF, ischemic
cause, and small body surface area were predictors of LCOS.
Therefore these patients remain at risk for requiring mechan-
ical circulatory support and should be screened appropri-
ately preoperatively (if possible) to determine ultimate
disposition. This would facilitate intraoperative decision
making with respect to the use of a long-term implantable
device versus short-term paracorporeal support. In addition,
such a screening process would highlight the need for strate-
gic placement of proximal coronary bypass grafts in patients
with ischemic MR, allowing for the potential subsequent in-
sertion of an left ventricular assist device outflow graft. We
suggest preoperative ‘‘optimization’’ of high-risk patients
undergoing mitral surgery who might benefit from diuresis,
afterload reduction, and time to recover from an acute ische-
mic insult. It is strikingly evident that the development of
postoperative LCOS in patients undergoing mitral valve sur-
gery has a dramatic effect on additional morbidity and mor-
tality, highlighting the need for a cautious and planned
approach in high-risk subjects.References
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